Thrombosis
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
Latest News
New recall for CoaguChek test strips issued
These CoaguChek XS PT test strips were distributed by Terrific Care and Medex but weren’t included in Roche Diagnostics’ original recall.
From the Journals
Impaired clot lysis associated with mild bleeding symptoms
From the Journals
Anticoagulation shows promise in concurrent lupus nephritis, thrombotic microangiopathy
Results come from the largest multicenter cohort study in these patients.
News
FDA approves ravulizumab for PNH
The U.S.
Conference Coverage
Phase 3 data support apixaban for cancer-associated VTE
The rate of major bleeding was similar with apixaban and dalteparin.
News
Rivaroxaban can reduce VTE in cancer patients
SAN DIEGO—In the phase 3 CASSINI trial, prophylaxis with rivaroxaban reduced the rate of venous thromboembolism (VTE) and VTE-related death in...
Conference Coverage
Rivaroxaban may reduce VTE risk in cancer patients
SAN DIEGO – The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.
Conference Coverage
Large cohort study IDs prognostic factors in thromboangiitis obliterans
CHICAGO – Ethnicity and limb infection are independent predictors of poor outcomes, including limb amputation, in TAO.
News
Data support apixaban for cancer-associated VTE, doc says
SAN DIEGO—Apixaban is as safe as, and more effective than, dalteparin for patients with cancer-associated venous thromboembolism (VTE), according...
From the Journals
AVERT: Apixaban reduced thromboembolism risk in cancer patients
Cancer patients treated with apixaban had a significantly lower rate of venous thromboembolism but a higher risk of major bleeds than did those...